712 North is a pre-clinical stage pharmaceutical company that develops modulators of the dynamic mitochondrial network for patients with Alzheimer’s and other diseases. Our goal is to drug a novel, proprietary mitochondrial target protease crucial for neuronal survival using small molecules and RNAi. The mechanism of action is genetically validated and functionally connected to tau, one of the hallmarks of Alzheimer’s pathophysiology. We have identified the biology by studying a genetic neurodegenerative disease of childhood blindness with the name of Autosomal Dominant Optic Atrophy (ADOA). 712 North leverages this orphan indication as fast-to-market strategy. In vivo data indicate that this mechanism of action is also engaged in other diseases, which is why we believe we have a unique drug discovery engine/platform technology allowing us to pursue discovery programs for other age-related diseases as well.

LEADERSHIP
Marcel V. Alavi, PhD, President & Chairman, is a scientist turned entrepreneur with more than a decade of hands-on research experience at leading medical research centers, such as the University of California in San Francisco, UCSF. Dr. Alavi was awarded his Ph.D. with summa cum laude from the Eberhard-Karls University Tuebingen in Germany and he holds a Master of Science degree from the Ludwig-Maximilian University Munich. Dr. Alavi received training in Protein Biochemistry, Cell Biology, Human Genetics, Pathology, and Bioinformatics. He has experience in Marketing and Communications, Business Development, Trademarks and Intellectual Property, FDA regulations, Drug Development, Science and Health Policies. Dr. Alavi is an inventor and has co-authored more than 20 peer-reviewed scientific publications. He has studied ADOA for more than 12 years, after which he founded 712 North to translate his research discoveries into therapies.

FINANCIALS
We are currently seeking seed funding to consolidate our patents and advance the drug development programs. We estimate we require in total $25M to $50M to obtain clinical proof-of-concept for the orphan indication in a phase II trial within the next 5 to 6 years. Should this opportunity fall within your investing interests, please don’t hesitate to contact me at (415) 489-8995 or at marcel@712north.com.

TIMELINES

---

1 THIS EXECUTIVE SUMMARY DOES NOT CONSTITUTE AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES OF 712 NORTH INC. (THE ”COMPANY”) TO ANYONE IN ANY STATE OR IN ANY JURISDICTION. ANY OFFER, SALE OR ISSUANCE OF ANY SECURITIES OF THE COMPANY SHALL ONLY BE MADE PURSUANT TO A DEFINITIVE PURCHASE AGREEMENT ENTERED INTO BETWEEN THE PURCHASER AND THE COMPANY. ANY OFFER TO INVEST IN THE SECURITIES OF THE COMPANY, AND ANY SUBSEQUENT SALE OF THE COMPANY’S SECURITIES, HAS NOT BEEN, AND WILL NOT BE, REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES ACT, AND ANY SECURITIES OF THE COMPANY WILL ONLY BE OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH ACTS.